Publications by authors named "Adena Pepich"
Article Synopsis
- High-risk neuroblastoma has a dismal outlook, underscoring the need for innovative treatment strategies, particularly targeting Rho GTPase signaling which has been linked to both the disease and resistance to therapies.
- The dual ROCK inhibitor RKI-1447 showed significant anti-cancer effects by reducing tumor growth, boosting cell death, and inhibiting key oncogenes like N-MYC in both lab and animal studies.
- Combining RKI-1447 with BET inhibitors like ABBV-075 enhanced treatment effects and helped in overcoming resistance, presenting a potential strategy to improve neuroblastoma therapies while minimizing side effects.
Neuroblastoma is an aggressive pediatric cancer with a high rate of metastasis to the BM. Despite intensive treatments including high-dose chemotherapy, the overall survival rate for children with metastatic neuroblastoma remains dismal. Understanding the cellular and molecular mechanisms of the metastatic tumor microenvironment is crucial for developing new therapies and improving clinical outcomes.
View Article and Find Full Text PDFDysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal expression is one of the strongest predictors of poor prognosis.
View Article and Find Full Text PDF